ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hardy, J.-F.
Right arrow Articles by Gagnon, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hardy, J.-F.
Right arrow Articles by Gagnon, L.

Ann Thorac Surg 1998;65:371-376
© 1998 The Society of Thoracic Surgeons

Original Articles: Cardiovascular

Prophylactic Tranexamic Acid and {epsilon}-Aminocaproic Acid for Primary Myocardial Revascularization

Jean-François Hardy, MD, Sylvain Bélisle, MD, Charles Dupont, MSc, François Harel, MSc, Danielle Robitaille, MD, Micheline Roy, RT, Lyne Gagnon, RT

Department of Anesthesia, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada,
Department of Biostatistics, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada,
Department of Hematology, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada

Accepted for publication July 16, 1997.

Dr Hardy, Montreal Heart Institute, 5000 Bélanger St, Montreal, PQ, Canada H1T 1C8 (e-mail: hardy@icm.umontreal.ca).

Background. The efficacy of prophylactic {epsilon}-aminocaproic acid and tranexamic acid to reduce transfusions after primary myocardial revascularization was evaluated in a teaching hospital context.

Methods. Patients (n = 134) received either {epsilon}-aminocaproic acid (15-g bolus + infusion of 1 g/h), high-dose tranexamic acid (10-g bolus + placebo infusion), or normal saline solution in a double-blind fashion. Anticoagulation and conduct of cardiopulmonary bypass were standardized.

Results. Tranexamic acid and {epsilon}-aminocaproic acid produced a significant reduction in postoperative blood loss compared with placebo (median loss, 438 mL, 538 mL, and 700 mL, respectively). Transfusion of red cells was similar in all three groups. Nonetheless, the percentage of patients receiving hemostatic blood products was significantly decreased in the {epsilon}-aminocaproic acid group compared with the placebo group (20% versus 43%; p = 0.03). Both tranexamic acid and {epsilon}-aminocaproic acid significantly decreased total exposure to allogeneic blood products compared with placebo (p = 0.01 and p = 0.05, respectively), and this reduction was clinically important (median exposure, 2, 2, and 7.5 units, respectively). Fibrinolysis was inhibited significantly in both treatment groups.

Conclusions. We conclude that either high-dose tranexamic acid or {epsilon}-aminocaproic acid effectively reduces transfusions in patients undergoing primary, elective myocardial revascularization.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1998 by The Society of Thoracic Surgeons.